Risks and outcomes of allogeneic hematopoietic stem cell transplantation for hematologic malignancies in patients with Human immunodeficiency virus Infection

The worldwide prevalence of Human Immunodeficiency Virus (HIV) is around 37 million and antiretroviral therapy (ART) has considerably improved survival in HIV infected patients with dramatic declines in morbidity and mortality since its availability1-3. Despite these improvements, about one million HIV related deaths occur annually. Persons living with HIV (PLHIV) are at a higher risk of developing both hematologic and solid organ malignancies as compared to the general population despite the use of ART4.

Source: Biology of Blood and Marrow Transplantation - March 25, 2019 Category: Hematology Authors: Shukaib Arslan, Mark R. Litzow, Nathan W. Cummins, Stacey A. Rizza, Andrew D. Badley, Willis Navarro, Shahrukh K. Hashmi Source Type: research